Clinical Trial Update: Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

Update on an early-stage trial evaluating the efficacy and safety of the therapeutic vaccine PEP223 in prostate cancer (Phase 1/2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• PEP223

Snippet

Sponsor: Pepscan Therapeutics | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: UNKNOWN